Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
Would you consider consolidative RT in patients with metastatic bladder cancer after near complete response after Keytruda?
Answer from: Radiation Oncologist at Community Practice
Generally, no I wouldn't, as I can't quantify the risk-to-benefit ratio given the paucity of data.
Sign in or Register to read more
20304
Related Questions
Would you consider treating a patient with prostate cancer and biopsy-proven involved inguinal nodes with radiation to the prostate/pelvis/groin?
What urethral dose constraints would you use off-trial for reirradiating the prostate using SBRT?
In platinum-refractory or multiply-relapsed NSGCT with 1–2 progressive sites and no good surgical option, is there a role for local radiotherapy (e.g., SBRT) to those sites?
Would you ever re-irradiate the groin/inguinal region?
When treating an inoperable urothelial cancer of the renal pelvis, what are your considerations when determining candidacy for SBRT?
Given the different rates of testosterone recovery, do you alter the duration of ADT when using Leuprorelin (GnRH Agonist) vs relugolix (GnRH antagonist) in patients with intermediate or high-risk prostate cancer who received definitive radiation?
In a patient with a synchronous prostate cancer and non-invasive urothelial carcinoma limited to the prostatic urethra is complete TUR and definitive prostate dose to standard prostate fields adequate treatment?
How do you manage prostatic adenocarcinoma after a subtotal resection?
For a patient with a rising PSA after prostatectomy with seminal vesicles being negative for disease at surgery, do you ever treat the prostate bed and seminal vesicle bed with different doses in an SIB plan?
What are your top takeaways from ASCO GU 2025?